Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 8.3%

Altamira Therapeutics Ltd (NASDAQ:CYTO) fell 8.3% on Tuesday . The company traded as low as $2.30 and last traded at $2.32. 175,723 shares changed hands during trading, a decline of 93% from the average session volume of 2,586,059 shares. The stock had previously closed at $2.53.

About Altamira Therapeutics (NASDAQ:CYTO)

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Recommended Story: What is the accumulation/distribution indicator?

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.